



#8
Election
8.19.03
PATENT

Customer No. 22,852
Attorney Docket No. 3495.0104-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

AUG 18 2003

TECH CENTER 1600/2900

In re Application of:)
)
Marc ALIZON et al.) Group Art Unit: 1648
)
Application No.: 09/986,634) Examiner: J. Parkin
)
Filed: November 9, 2001)
)
For: NUCLEIC ACID-BASED METHODS FOR THE DETECTION
OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 (HIV-2)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

RESPONSE TO RESTRICTION REQUIREMENT

In a restriction requirement dated June 16, 2003, the Examiner required restriction under 35 U.S.C. § 121 between Group 1, claims 16-21; Group II, claims 22-25; and Group III, claims 26-29.

Applicants provisionally elect to prosecute Group II, claims 22-25, drawn to a method for preparing a recombinant HIV-2 peptide, classified in class 435, subclass 69.1.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: August 14, 2003

By: 

Salvatore J. Arrigo

Reg. No. 46,063

Telephone: 202-408-4160

Facsimile: 202-408-4400

E-mail: arrigos@finnegan.com

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com